Aptagen, LLC
S6-1 (ID# 8061)
![](https://www.aptagen.com/wp-content/uploads/S6-1.jpg)
DNA
human malignant glioma cell line SHG44
Cells
44 ± 15 nM (reported value)
4.5 g/L of glucose, 0.01 M phosphate buffered saline, and 5 mM of MgCl2
37 °C°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
5’-dTpdCpdApdApdGpdTpdCpdApdCpdApdGpdGpdTpdTpdCpdCpdApdGpdGpdTpdApdApdTpdApdCpdCpdTpdApdApdGpdGpdGpdTpdApdTpdGpdCpdTpdCpdTpdCpdGpdCpdCpdTpdApdTpdTpdApdTpdApdTpdGpdGpdApdGpdCpdApdCpdGp-3’
![](/wp-content/uploads/apta-sequence-abbr.png)
60
18474
583800
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Miyakawa, Shin, et al. "Structural and molecular basis for hyperspecificity of RNA aptamer to human immunoglobulin G." RNA Journal 14,(2008): 1154-1163.
Have your aptamer oligo synthesized ORDER
We are always looking for ways to improve. Please tell us what you think.